Crizotinib (Xalkori) - Oncology Nurse Advisor

Crizotinib (Xalkori)

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow examines crizotinib (Xalkori), indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive and metastatic NSCLC whose tumors are ROS1-positive.

Table of Contents

Slide 4: Dosage and Administration
Slide 14: Cautions, Effects, and Interactions
Slide 22: What to Tell Your Patient
Slide 31: Reference

Next hm-slideshow in Slides